Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test.
Vasseur D, Sassi H, Bayle A, Tagliamento M, Besse B, Marzac C, Arbab A, Auger N, Cotteret S, Aldea M, Blanc-Durand F, Géraud A, Gazzah A, Loriot Y, Hollebecque A, Martín-Romano P, Ngo-Camus M, Nicotra C, Ponce S, Sakkal M, Caron O, Smolenschi C, Micol JB, Italiano A, Rouleau E, Lacroix L. Vasseur D, et al. Among authors: gazzah a. Cells. 2022 Jun 11;11(12):1901. doi: 10.3390/cells11121901. Cells. 2022. PMID: 35741030 Free PMC article. Review.
Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs.
Rouanne M, Massard C, Hollebecque A, Rousseau V, Varga A, Gazzah A, Neuzillet Y, Lebret T, Soria JC. Rouanne M, et al. Among authors: gazzah a. Eur J Cancer. 2013 Jan;49(2):431-8. doi: 10.1016/j.ejca.2012.08.008. Epub 2012 Sep 6. Eur J Cancer. 2013. PMID: 22959468 Clinical Trial.
[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].
Baldini C, Duchemann B, Hollebecque A, Routier É, Varga A, Gazzah A, Bahleda R, Besse B, Soria JC, Massard C. Baldini C, et al. Among authors: gazzah a. Bull Cancer. 2012 Sep;99(9):865-74. doi: 10.1684/bdc.2012.1632. Bull Cancer. 2012. PMID: 25471668 Free article. Review. French.
Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.
Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, Ileana E, Massard C, Vielh P, Soria JC, Besse B. Kossai M, et al. Among authors: gazzah a. Lung Cancer. 2015 Sep;89(3):306-10. doi: 10.1016/j.lungcan.2015.06.014. Epub 2015 Jun 22. Lung Cancer. 2015. PMID: 26160757
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N, Planchard D, Bluthgen MV, Gazzah A, Pannet C, Nicotra C, Auclin E, Soria JC, Besse B. Remon J, et al. Among authors: gazzah a. Ann Oncol. 2017 Apr 1;28(4):784-790. doi: 10.1093/annonc/mdx017. Ann Oncol. 2017. PMID: 28104619 Free article. Clinical Trial.
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC. Massard C, et al. Among authors: gazzah a. Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1. Cancer Discov. 2017. PMID: 28365644 Clinical Trial.
90 results